Recent events
Recent events tied to this brand in public sources.
Back to profile12 entries
2026
WuXi Biologics wins two 2026 Hong Kong ESG Reporting Awards
WuXi Biologics announced that it won the Best ESG Report Award (Large Market Cap) and the Excellence in Environmental Achievement Award at the 2026 Hong Kong ESG Reporting Awards.
2021
Immune-Onc completes approximately $73 million funding round
Immune-Onc completed a B1/B2 funding round of approximately $73 million, led by Haisong Capital, with other investors also participating. The funds are primarily for advancing and expanding its drug pipeline globally and supporting operations in the United States and China.
2021
WuXi Biologics wins 2021 CMO Leadership Awards
WuXi Biologics was named a winner of the 2021 CMO Leadership Awards in all six core categories and across the Big Pharma, Small Pharma, and Overall respondent groups.
2021
WuXi Biologics launches GMP operation at MFG5
WuXi Biologics launched GMP operation at its MFG5 drug-substance manufacturing facility in China, which has a capacity of 36,000 liters and brought the company’s current capacity to 90,000 liters.
2020
WuXi Biologics received GMP certification from Brazil's ANVISA
WuXi Biologics announced that it had received Good Manufacturing Practice certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA).
2020
WuXi Biologics signs land deal for Worcester manufacturing facility
WuXi Biologics and the Worcester Business Development Corporation announced the signing of a land deal for WuXi Biologics' clinical and commercial manufacturing facility in Worcester. The facility was planned to become operational in 2022 and create 150 jobs.
2020
WuXi Biologics completed acquisition of Bayer manufacturing plant
WuXi Biologics announced that it completed the acquisition of a drug product manufacturing plant in Leverkusen, Germany, from Bayer. WuXi Biologics took over plant operations and purchased the plant equipment.
2020
WuXi Biologics and Vir Biotechnology partner on COVID-19 antibody development and production
WuXi Biologics and Vir Biotechnology announced a collaboration agreement to develop and produce fully human monoclonal antibodies for treating COVID-19. WuXi Biologics will support cell-line, process and formulation development and early clinical production; the agreement provides WuXi Biologics commercialization rights in Greater China if the antibodies receive regulatory approval, while Vir holds rights in other global markets.
2019
WuXi Biologics receives Ireland investor award
WuXi Biologics announced that it received the “Special Award to Investors in Ireland” at the 2019 Global Business Summit held by Asia Matters.
2019
WuXi Biologics and Convalife partner on bispecific antibody development
WuXi Biologics and Convalife announced a collaboration to develop an innovative anti-tumor bispecific antibody. Convalife will use WuXi Biologics' integrated biopharmaceutical capabilities, while WuXi Biologics will provide technical support for discovery, development and manufacturing.
2019
WuXi Biologics and Newcode Therapeutics partner on ARX788 development and production
WuXi Biologics and Newcode Therapeutics announced a strategic collaboration supporting ARX788's phase III clinical research and large-scale commercial production. WuXi Biologics will provide drug-substance and drug-product work for phase III clinical samples, process characterization and validation, and large-scale commercial production services.
2019
WuXi Biologics' DP3 facility begins GMP commercial production
WuXi Biologics announced that its ADC drug substance and drug product facility DP3 had officially begun GMP commercial production. The article states that the facility can produce up to 100 kg of ADC conjugated drug substance and fill and lyophilize up to 500,000 vials annually.